Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PFE    crawled date : 2021 - 09 - 29    save search
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M twitter stocktwits trandingview |
Health Technology
 | | O: 0.42% H: 1.09% C: 0.72%
positive results vaccine phase 3 topline order
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs
Published: 2021-09-29 (Crawled : 09:00) - biospace.com/
GLAXF | News | $20.2 -14.18% 510 twitter stocktwits trandingview |
Health Technology
 | | O: -2.93% H: 0.0% C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M twitter stocktwits trandingview |
Health Technology
 | | O: 0.42% H: 1.09% C: 0.72%
GSK | News | $39.75 1.22% 0.0% 1.6M twitter stocktwits trandingview |
Health Technology
 | | O: 0.16% H: 0.81% C: 0.58%
drug
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.